Guangzhou Innogen Signs Licensing Deal Worth Over $1 Billion
The Hong Kong-listed company signed a licensing deal for a diabetes drug valued at more than $1 billion.
The Hong Kong-listed company signed a licensing deal for a diabetes drug valued at more than $1 billion.